ONCT - Promising Preclinical Results From Blood Cancer Propel Oncternal To Buy Rating | Benzinga
HC Wainwright has upgraded Oncternal Therapeutics Inc (NASDAQ: ONCT) to Buy from Neutral with a price target of $2.
At the European Hematology Association meeting earlier this year, Oncternal unveiled initial findings from preclinical investigations that assessed T cells and natural killer (NK) cells expressing the company's ROR1 CAR, featuring the antigen-binding segment of zilovertamab.
NK92 cells engineered with the anti-ROR1 CAR exhibited degranulation when exposed to ROR1+ cancer cells in vitro.
Furthermore, anti-ROR1 CAR T cells displayed statistically significant anti-tumor activity against the rapidly proliferating mantle cell lymphoma (MCL) line known as JeKo-1 in vivo.
Although cancer cell ...